Antibody Drug Conjugates Contract Manufacturing Market Report 2026

The antibody drug conjugates contract manufacturing market size has grown strongly in recent years. It will grow from $10.45 billion in 2025 to $11.45 billion in 2026 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to growth in targeted cancer therapies, complexity of adc production, limited in-house manufacturing capabilities, early clinical success of adcs, regulatory compliance requirements.

The antibody drug conjugates contract manufacturing market size is expected to see strong growth in the next few years. It will grow to $16.5 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to expanding oncology pipelines, increasing approvals of adc therapies, rising demand for commercial-scale production, investment in specialized manufacturing facilities, long-term cdmo partnerships. Major trends in the forecast period include rising outsourcing of complex biologic manufacturing, growing demand for oncology-focused cdmo services, increased focus on high-potency payload handling, expansion of clinical-stage adc manufacturing, higher adoption of advanced conjugation technologies.

The expanding biopharmaceutical industry is anticipated to drive the growth of the antibody-drug conjugates contract manufacturing market in the coming years. The biopharmaceutical sector focuses on developing, producing, and commercializing drugs derived from biological sources, employing biotechnology and molecular biology to create innovative therapies and treatments. This industry is growing due to rapid advancements in biotechnology, increasing demand for personalized medicine, and rising investments in research and development for novel therapies and treatments. Antibody-drug conjugates (ADCs) contract manufacturing supports the biopharmaceutical sector by providing specialized production services that facilitate the development and commercialization of these advanced therapies. Biopharmaceutical companies can efficiently scale up production and maintain high-quality standards while concentrating on their core research and development activities. For example, in June 2023, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based trade association representing the pharmaceutical industry in Europe, total pharmaceutical production in Europe reached €390.0 billion ($422,803 million) in 2023, up from €363.3 billion ($393,857 million) in 2022. Thus, the growing biopharmaceutical industry is driving the expansion of the antibody-drug conjugates contract manufacturing market.

Major companies operating in the antibody-drug conjugates contract manufacturing market are concentrating on developing innovative solutions, such as single-use reactors, to boost production flexibility, minimize contamination risks, and simplify the manufacturing process, ultimately enhancing the efficiency and scalability of ADC production. Single-use reactors are transforming the field of antibody-drug conjugates (ADCs) contract manufacturing by offering a flexible, efficient, and contamination-free approach for producing these complex biologics. For example, in September 2024, MilliporeSigma, a US-based life sciences company, introduced the Mobius ADC Reactor, a single-use reactor. The Mobius ADC Reactor is specifically engineered to manufacture antibody-drug conjugates (ADCs) efficiently. It incorporates advanced mixing and control technologies that streamline conjugation, improve scalability, and ensure greater consistency. This innovative reactor enables higher yields and better quality control in ADC production, meeting the increasing demand for targeted cancer therapies with enhanced safety and efficacy.

In March 2024, Johnson & Johnson, a US-based pharmaceutical, biotechnology, and medical technologies corporation, acquired Ambrx Biopharma Inc. for $2 billion. Through this acquisition, Johnson & Johnson intends to strengthen its pipeline of advanced therapies by incorporating Ambrx's innovative drug development technologies and broadening its biologics and targeted treatment capabilities. Ambrx Biopharma Inc. is a US-based biotechnology firm that specializes in developing state-of-the-art therapies, including antibody-drug conjugates (ADCs).

Major companies operating in the antibody drug conjugates contract manufacturing market are Lonza Group AG, Catalent Inc., Recipharm AB, Curia, KBI Biopharma, Alcami Corporation, BioVectra Inc., Axplora, Abzena PLC, Cerbios-Pharma SA, Aurigene Pharmaceutical Services Ltd., Sterling Pharma Solutions, Formosa Laboratories, Avid Bioservices Inc., EirGenix Inc., Creative Biolabs, Sartorius AG, Sigma-Aldrich, ImmunoGen Inc., Eli Lilly and Company.

North America was the largest region in the antibody drug conjugates contract manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibody drug conjugates contract manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the antibody drug conjugates contract manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the antibody drug conjugates contract manufacturing market by increasing costs of imported biologic raw materials, linkers, and cytotoxic payload components. Clinical and commercial manufacturing phases are most affected, particularly in regions reliant on international supply chains. Higher tariffs may increase development costs. However, tariffs are encouraging regional manufacturing expansion and localized supply chains.

The antibody drug conjugates contract manufacturing market research report is one of a series of new reports that provides antibody drug conjugates contract manufacturing market statistics, including antibody drug conjugates contract manufacturing industry global market size, regional shares, competitors with a antibody drug conjugates contract manufacturing market share, detailed antibody drug conjugates contract manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the antibody drug conjugates contract manufacturing industry. This antibody drug conjugates contract manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Antibody-drug conjugates (ADC) contract manufacturing involves outsourced production services offered by specialized contract development and manufacturing organizations (CDMOs) to produce antibody-drug conjugates. ADCs are intricate biopharmaceuticals that link an antibody with a cytotoxic drug, engineered to target and eliminate specific cancer cells while reducing harm to healthy cells.

The main types of antibody-drug conjugates contract manufacturing are immunoglobulin G1 (IgG1) and immunoglobulin G4 (IgG4). Immunoglobulin G1 (IgG1) is one of the four subclasses of Immunoglobulin G (IgG), a type of antibody present in the blood and extracellular fluid. The various linkers include cleavable linkers and non-cleavable linkers, used for multiple conditions such as myeloma, lymphoma, and breast cancer, among others, and are applied across several phases such as clinical and commercial.

The antibody drug conjugates contract manufacturing market includes revenues earned by entities by providing process development, scale-up and manufacturing, analytical testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.